Many of the companies developing drug therapies for non-alcoholic steatohepatitis (NASH) also are investigating non-invasive ways to diagnose the disease and its precursor, non-alcoholic fatty liver disease (NAFLD). Blood tests or scans are showing some promise to replace liver biopsy as the diagnostic standard in this setting, but early data are inconclusive on their accuracy.
EASL’s NASH Highlights
(Also see "Pfizer Thinks First-In-Class KHK Mechanism Could Work For NASH, Diabetes" - Scrip, 15 April, 2019.)
(Also see "Gilead Increasingly Seems Focused On Combo Therapy In NASH" - Scrip, 12 April, 2019.)
(Also see "Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’" - Scrip, 12 April, 2019.)
(Also see "Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen" - Scrip, 11 April, 2019.)
(Also see "Genfit Hopes To Make Case For First-Line Treatment In NASH" - Scrip, 4 April, 2019.)
The US FDA’s draft guidance for NASH R&D, issued last December, recommends that drug sponsors work on such diagnostic tools...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
